Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > ABT 263

ABT 263

ABT-263 is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2 and Bcl-xL, which play a key role in regulating programmed cell death.
This agent has shown promise in the treatment of various cancers, including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and small-cell lung cancer.
PubCompare.ai's AI-driven platform can enhance the reproducibility and accuracy of ABT-263 research by helping researchers quickly locate the best protocols from literature, preprints, and patents, using intelligent comparisons to identify the optimal products.
The user-friendly platform can streamline ABT-263 studies, enabling researchers to more efficiently explore this important therapeutic target.

Most cited protocols related to «ABT 263»

1
DT2216 Suppresses MOLT-4 T-ALL Xenograft Tumor Growth
Cited 8 times
To test the effect of DT2216 on tumor growth in MOLT-4 T-ALL xenografts, MOLT-4 T-ALL cells were harvested and suspended in regular RPMI medium and mixed with Matrigel (1:1) (Cat. No. 356231, Corning, Corning, NY, USA). The cells (5 × 106 cells) suspended in 100 μL of RPMI medium-Matrigel mixture were subcutaneously (s.c.) implanted in the right flank of CB-17 SCID mice. Tumor growth was monitored daily and tumors were measured twice a week using Vernier caliper or digital calipers. Tumor volume was determined using the formula; [(L × W2) × 0.5], where L is length/long dimension in millimeter (mm) and W is the width/short dimension in mm. The treatment started once the average tumor volume reached 150–200 mm3. The animals were randomly assigned into separate groups (n = 6–8) in a way that each group had nearly equal starting average tumor volume. Mice were weighed twice a week and the treatments were given according to average mouse weight within each group before initiation of treatment. DT2216 and ABT263 for i.p. administration were formulated in 50% PHOSAL 50 PG, 45% MIGLYOL® 810 N and 5% Polysorbate 80. DT2216 and ABT263 were administered via i.p. injection at 15 mpk/week in 100 μL vehicle (Extended Data Fig. 8). ABT263 for oral administration was formulated in 10% ethanol, 30% PEG 400 and 60% PHOSAL 50 PG (Fig. 4). Control mice received 100 μL vehicle via i.p. injection. The mice were euthanized when the maximum tumor size in a mouse reached the humane endpoint according to institutional policy concerning tumor endpoints in rodents. In addition, to prevent excessive pain or distress, the mice were euthanized if the tumors became ulcerated or the mice showed any signs of ill health. Mice were euthanized by CO2 suffocation followed by cervical dislocation and various tissues including tumors were harvested for further analyses.
Khan S., Zhang X., Lv D., Zhang Q., He Y., Zhang P., Liu X., Thummuri D., Yuan Y., Wiegand J.S., Pei J., Zhang W., Sharma A., McCurdy C.R., Kuruvilla V.M., Baran N., Ferrando A.A., Kim Y.M., Rogojina A., Houghton P.J., Huang G., Hromas R., Konopleva M., Zheng G, & Zhou D. (2019). A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature medicine, 25(12), 1938-1947.
Publication 2019
ABT 263 Administration, Oral Animals Asphyxia Cells DT2216 Ethanol Fingers Heterografts Joint Dislocations matrigel miglyol 810 Molting Mus Neck Neoplasms Pain polyethylene glycol 400 Polysorbate 80 Rodent SCID Mice Tissues
2
Competitive Repopulation Assay for Murine Hematopoietic Stem Cells
Cited 6 times
CD45.2 mice were exposed to a sublethal dose (6.0 Gy) of TBI or sham irradiation and then treated with vehicle or ABT263 as shown in Figure 3a,g. BMCs were isolated and mixed with 2 × 105 competitive BMCs pooled from three CD45.1 mice. The cell mixture was then transplanted into lethally irradiated (9.5 Gy TBI) CD45.1 recipients via retro-orbital injection of the venous sinus. For the normal aging study, 50 freshly sorted LT-HSCs from young and aged C57BL/6 mice treated with vehicle or ABT263 were mixed with 3 × 105 competitive BMCs pooled from three CD45.1 mice, and the cell mixture was then transplanted into lethally irradiated CD45.1 recipients via retro-orbital injection of the venous sinus. Donor-cell engraftment in the recipients was analyzed at various times after transplantation as previously described4 (link),42 . For secondary BMT, 1 × 106 BMCs were harvested from each primary recipient 4 months after primary BMT and were then transplanted into a lethally irradiated recipient as described above. Donor-cell engraftment in both primary and secondary recipient peripheral blood was analyzed as previously described4 (link),42 .
Chang J., Wang Y., Shao L., Laberge R.M., Demaria M., Campisi J., Janakiraman K., Sharpless N.E., Ding S., Feng W., Luo Y., Wang X., Aykin-Burns N., Krager K., Ponnappan U., Hauer-Jensen M., Meng A, & Zhou D. (2015). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature medicine, 22(1), 78-83.
Publication 2015
ABT 263 BLOOD Cells Donors Mice, Inbred C57BL Mus Sinuses, Nasal Stem Cells, Hematopoietic Transplantation Transplant Recipients Veins
3
Ex vivo Pituitary Culture Assay
Cited 4 times
For ex vivo pituitary culture, anterior pituitaries were isolated from Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryos at 18.5 dpc, placed on top of 0.2 µM Whatman filters (SLS) in 24 well plates containing 500 µl of media (DMEM-F12 (Gibco), 1% Pen/Strep (Sigma) and 1% FBS (PAA) supplemented with either ABT-737 at 2.5 µM (Adooq Bioscience), ABT-263 at 1 µM (Caymen Chemical) or vehicle. Anterior pituitaries were cultured for 3–4 days, changing media every day and subsequently processed for histological analysis.
Gonzalez-Meljem J.M., Haston S., Carreno G., Apps J.R., Pozzi S., Stache C., Kaushal G., Virasami A., Panousopoulos L., Mousavy-Gharavy S.N., Guerrero A., Rashid M., Jani N., Goding C.R., Jacques T.S., Adams D.J., Gil J., Andoniadou C.L, & Martinez-Barbera J.P. (2017). Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma. Nature Communications, 8, 1819.
Full text: Click here
Publication 2017
ABT-737 ABT 263 Embryo Pituitary Hormones, Anterior Streptococcal Infections
4
Cell Line Authentication and Drug Treatment
Cited 4 times
Human CRC cell lines were obtained from the American Type Culture Collection (Manassas, VA). FBW7-KO HCT116 cells were obtained from Horizon Discovery (Cambridge, UK). PUMA-KO HCT116 cells were previously described (18 (link)). Cell lines were authenticated in 2015 by genotyping, western blotting of protein expression, and routine detection of mycoplasma contamination by PCR. All cell lines were maintained at 37°C and 5% CO2 in McCoy’s 5A modified media (Invitrogen) supplemented with 10% defined FBS (HyClone), 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). For drug treatment, cells were plated in 12-well plates at 20–30% density 24 hr before treatment. Chemicals, including regorafenib, sorafenib, UCN-01, sunitinib, roscovitine, sulindac sulfide, etoposide, MG132, ABT-737, ABT-263, SB216736, TW37 (Selleck Chemicals), cycloheximide (CHX; Sigma), and UMI-77 (19 (link),20 (link)), were solubilized in DMSO and diluted to appropriate concentrations with the cell culture medium. TRAIL (XcessBio, San Diego, CA) was diluted with distilled water.
Tong J., Wang P., Tan S., Chen D., Nikolovska-Coleska Z., Zou F., Yu J, & Zhang L. (2017). Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer research, 77(9), 2512-2521.
Publication 2017
ABT-737 ABT 263 Cell Culture Techniques Cell Lines Cells Culture Media Cycloheximide Etoposide HCT116 Cells Homo sapiens MG 132 Mycoplasma Penicillins Pharmaceutical Preparations Proteins Puma regorafenib Roscovitine Sorafenib Streptomycin Sulfoxide, Dimethyl sulindac sulfide Sunitinib TNFSF10 protein, human UCN 01 UMI-77
5
Xenograft Tumor Model for Anticancer Drugs
Cited 4 times
5 × 105 MGPP-3 cells suspended 1:1 in Matrigel® (Corning Inc., Corning, NY, U.S.A.) were implanted subcutaneously into the flanks of 6–8 week-old SCID SHO mice as previously described [28 (link)]. Treatment was performed intraperitoneally 3 times a week for 2 weeks. For intraperitoneal application ABT263 and TIC10/ONC201 were dissolved in 80% Cremophor EL (SIGMA, St. Louis, MO) and 20% Ethanol (Pharmco-Aaper, Brookfield, CT) (v/v).
Karpel-Massler G., Bâ M., Shu C., Halatsch M.E., Westhoff M.A., Bruce J.N., Canoll P, & Siegelin M.D. (2015). TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Oncotarget, 6(34), 36456-36471.
Full text: Click here
Publication 2015
ABT 263 Cells cremophor EL Ethanol matrigel ONC201 SCID Mice TIC10 compound

Most recents protocols related to «ABT 263»

1
Evaluating Antifibrotic Effects of ABT-263
Beginning after fibrosis was established (4 weeks after silica or 10 weeks after the initial bleomycin dose), mice were administered 100 mg/kg ABT-263 in DMSO and sterile corn oil or vehicle (sterile corn oil with DMSO) by daily oral gavage for 28 days. Mice underwent micro-CT scanning prior to the induction of fibrosis, prior to treatment with ABT-263, and at study termination (Skyscan 1276, Bruker MicroCT). Images were acquired at 35 μm resolution, with x-ray tube voltage 50 kV, current 500 A, exposure time 900 ms, with 0.5 mm aluminum filter and a 0.7° rotation step. Scans were reconstructed as described (29 (link)). Fibrosis was assessed by measuring nonaerated lung tissue volume by micro-CT, lung collagen quantified by hydroxyproline in the upper right lobe (12 (link), 29 (link)), and semiquantitative stereology-based point-counting assessment of fibrosis in the left lung of formalin-fixed, paraffin-embedded, 5 μm sections stained with Masson’s trichrome and imaged by Aperio Scanning (Leica Biosystems) (74 (link)). PDGFRα+ fibroblast numbers were measured by flow cytometry (12 (link)).
Cooley J.C., Javkhlan N., Wilson J.A., Foster D.G., Edelman B.L., Ortiz L.A., Schwartz D.A., Riches D.W, & Redente E.F. (2023). Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis. JCI Insight, 8(3), e163762.
Full text: Click here
Publication 2023
ABT-100 ABT 263 Aluminum Bleomycin Collagen Corn oil Fibroblasts Fibrosis Flow Cytometry Formalin Hydroxyproline Lung Lung Volumes Mus Paraffin Embedding Platelet-Derived Growth Factor alpha Receptor Radiography Silicon Dioxide Sterility, Reproductive Sulfoxide, Dimethyl Tissues Tube Feeding X-Ray Microtomography
2
Preparation and Culture of Precision-Cut Lung Slices
Healthy human lung tissue was obtained from Donor Alliance, and IPF tissue was obtained from lung biopsies or explanted lungs from confirmed cases of IPF (IRB 11-1664) as described previously (74 (link)). Tissue from patients with silicosis was obtained after lung transplant as described previously (75 (link)). For the generation of PCLS, freshly explanted healthy or IPF lungs were kept on ice and processed within 24 hours. Peripheral sections of lungs were inflated with low–melting point agarose (MilliporeSigma) by cannulation of a visible bronchus; then 6 × 6 × 6 mm cubes were cut from the lung, embedded in low–melting point agarose, and sectioned using a vibratome (Leica). We cultured 300 μm slices in Eagle minimal essential medium (EMEM, Lonza) with 10% heat-inactivated fetal bovine serum (FBS, Atlanta Biologicals) and 1% penicillin/streptomycin/l-glutamine with or without ABT-263 (5 μM, Medchemexpress) for 24 hours.
Cooley J.C., Javkhlan N., Wilson J.A., Foster D.G., Edelman B.L., Ortiz L.A., Schwartz D.A., Riches D.W, & Redente E.F. (2023). Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis. JCI Insight, 8(3), e163762.
Full text: Click here
Publication 2023
ABT 263 Biological Factors Biopsy Bronchi Cannulation Cuboid Bone Eagle Glutamine Homo sapiens Lung Lung Transplantation Patients Penicillins Sepharose Silicosis Streptomycin Tissue Donors Tissues
3
Quantitative Analysis of Apoptosis Regulators
RNA was isolated from enriched Lin– cells or in vitro fibroblasts using the RNeasy kit per manufacturer guidelines (QIAGEN). qPCR was performed using Quantitect reverse transcription kit (QIAGEN). Primers for the following were used (Supplemental Table 4): Bcl-2, Bcl2l1 (Bcl-xl), Bcl2l2 (Bcl-w), Mcl-1, Bax, Bak1, Bid, Bcl2l11 (Bim), and Acta2 (α-SMA) (Integrated DNA Technologies). Data were analyzed using the ΔΔCt method and normalized to Gusb (Integrated DNA Technologies).
Cells were treated with ABT-263 (Medchemexpress) in DMEM (5 μM, mouse) or in EMEM (1 μM, human) with 0.25% FBS for the final 24 hours or 1 μM staurosporine (MilliporeSigma) for the final 5 hours. After a total of 72 hours, caspase-3 and -7 activity was measured by luminescence assay (Caspase-Glo 3/7, Promega) and read on a Biotek FLX800 microplate fluorescence reader. A concentration of 5 μM ABT-263 was used for mouse samples as 1 μM did not demonstrate increased apoptosis (data not shown).
Cooley J.C., Javkhlan N., Wilson J.A., Foster D.G., Edelman B.L., Ortiz L.A., Schwartz D.A., Riches D.W, & Redente E.F. (2023). Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis. JCI Insight, 8(3), e163762.
Full text: Click here
Publication 2023
ABT 263 ACTA2 protein, human Apoptosis BAK1 protein, human bcl-X Protein BCL2 protein, human Caspase-7 Caspase 3 Cells Fibroblasts Fluorescence Homo sapiens Luminescent Measurements Mus Oligonucleotide Primers Promega Reverse Transcription Staurosporine
4
Evaluation of Anticancer Compounds
Veliparib was provided by AbbVie. Etoposide, GSK461364, ABT-263, DMXAA and C178 were purchased from Cayman Chemical.
Liu Y., Pagacz J., Wolfgeher D.J., Bromerg K.D., Gorman J.V, & Kron S.J. (2023). Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells. Journal for Immunotherapy of Cancer, 11(2), e005862.
Publication 2023
ABT 263 Caimans Etoposide GSK 461364 vadimezan veliparib
5
Xenograft Pancreatic Cancer Mouse Model
Six weeks old nude (Rj:NMRI-Foxn1 nu/nu) female mice were used for xenograft experiments. Five million Panc1 cells, in 25% of matrigel (Sigma Aldrich), were subcutaneously injected into the flank of mice. Treatment: gemcitabine at 100 mg/kg three times a week for Fig. 3a-b and gemcitabine at 100 mg/kg or 50 mg/kg per intraperitoneal injection, once a week, and/or ABT-263 at 35 mg/kg or 50 mg/kg, per gavage, twice a week for Fig. 6. Prior to treatments, randomized groups with an average tumor size of 80 mm3 were defined. Tumors were measured after 5 weeks of treatment. Tumor volume was calculated using the following formula: V = a*b*c/2, where “a” is the longest diameter, “b” is the shortest one, and c the depth. Relative tumor volumes (vs tumor volume at the beginning of the treatments) were then calculated. Mice were maintained in laminar-flow boxes under standard conditions (standard diet and water ad libitum) in our specific pathogen-free animal house. Experiments were performed according to animal care guidelines of European and French laws. Protocols were authorized by the local animal ethic evaluation committee (CECCAPP:CLB_2017_041) and by the French ministry of education and research (APAFIS#12774).
Jaber S., Warnier M., Leers C., Vernier M., Goehrig D., Médard J.J., Vindrieux D., Ziegler D.V, & Bernard D. (2023). Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy. Molecular Biomedicine, 4, 4.
Full text: Click here
Publication 2023
ABT 263 Animals Cells Diet Ethics Committees Europeans forkhead box N1 protein, human Gemcitabine Heterografts Injections, Intraperitoneal Magnetic Resonance Imaging matrigel Mice, Nude Mus Neoplasms Specific Pathogen Free Tube Feeding Woman

Top products related to «ABT 263»

1
Abt 263 by Selleck Chemicals
Sourced in United States, Germany, China
ABT-263 is a laboratory research chemical produced by Selleck Chemicals. It is a small molecule inhibitor. The core function of ABT-263 is to inhibit apoptosis regulators.
2
Abt 199 by Selleck Chemicals
Sourced in United States, Germany
ABT-199 is a small molecule inhibitor that targets the BCL-2 protein. It is primarily used for research purposes in the laboratory setting.
3
Abt 737 by Selleck Chemicals
Sourced in United States, Germany
ABT-737 is a laboratory compound used in scientific research. It functions as a selective inhibitor of the Bcl-2 family of anti-apoptotic proteins. The core function of ABT-737 is to modulate apoptosis, a fundamental cellular process.
4
Abt 263 by Apexbio
Sourced in United States
ABT-263 is a small molecule that inhibits the activity of the BCL-2 family of proteins. It is commonly used in research applications to study apoptosis and cancer cell biology.
5
Abt 263 by MedChemExpress
Sourced in United States
ABT-263 is a selective and potent small molecule inhibitor of the Bcl-2 family of proteins. It functions by binding to and inhibiting the anti-apoptotic proteins Bcl-2, Bcl-xL, and Bcl-w.
6
Abt 263 navitoclax by Selleck Chemicals
Sourced in United States, Germany
ABT-263 (Navitoclax) is a laboratory research compound developed by Selleck Chemicals. It functions as a selective inhibitor of the anti-apoptotic Bcl-2 family proteins.
7
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
8
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
9
A 1210477 by Selleck Chemicals
Sourced in United States, Germany
A-1210477 is a lab equipment product. It is a multi-purpose device designed for use in various laboratory settings. The core function of this equipment is to perform specific tasks required in the laboratory environment.
10
Cremophor el by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, Macao, Spain, Israel, France, Brazil, India, Austria
Cremophor EL is a nonionic surfactant used as a solubilizing agent in pharmaceutical and cosmetic formulations. It is a polyoxyethylene castor oil derivative that increases the solubility of hydrophobic compounds in aqueous solutions. Cremophor EL is commonly used in various drug delivery systems to improve the solubility and bioavailability of poorly water-soluble drugs.

More about "ABT 263"

ABT-263, also known as Navitoclax, is a small-molecule inhibitor of the anti-apoptotic proteins Bcl-2 and Bcl-xL, which play a crucial role in regulating programmed cell death.
This compound has shown promise in the treatment of various cancers, including chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and small-cell lung cancer.
To enhance the reproducibility and accuracy of ABT-263 research, researchers can utilize PubCompare.ai's AI-driven platform.
This user-friendly tool helps researchers quickly locate the best protocols from literature, preprints, and patents, using intelligent comparisons to identify the optimal products.
By streamlining ABT-263 studies, researchers can more efficiently explore this important therapeutic target.
In addition to ABT-263, related compounds such as ABT-199 (Venetoclax) and ABT-737 have also been investigated for their potential in targeting the Bcl-2 family of proteins.
These molecules can be used in combination with other agents, such as DMSO (dimethyl sulfoxide) and FBS (fetal bovine serum), to optimize experimental conditions.
Furthermore, the A-1210477 compound, which is a selective Bcl-xL inhibitor, can be used in conjunction with ABT-263 to better understand the specific roles of Bcl-2 and Bcl-xL in regulating apoptosis.
The use of Cremophor EL, a solubilizing agent, may also be relevant in the formulation and delivery of these compounds.
By incorporating these relevant terms, abbreviations, and subtopics, researchers can enhance their understanding and exploration of the ABT-263 compound and its potential therapeutic applications.